Fig. 4: Cellular effects in the GCL following CIR and montelukast treatment. | Cell Death & Disease

Fig. 4: Cellular effects in the GCL following CIR and montelukast treatment.

From: The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain

Fig. 4

a A microphotograph of NeurotraceTM in the dentate gyrus. b Neurons were quantified in the GCL where a significant interaction was observed. c Proliferating cells, assessed by Ki-67+ staining. d Ki-67+ quantification in the hippocampal neurogenic SGZ. e Newborn cells, measured as total numbers of DCX+ cells. f DCX+ quantification in the SGZ. a Scale bar 20 µm. b ncontrol vehicle = 8, ncontrol montelukast = 9, nCIR vehicle = 6, nCIR montelukast = 6. c Scale bar 50 µm. d ncontrol vehicle = 9, ncontrol montelukast = 8, nCIR vehicle = 5, nCIR montelukast = 4. e Scale bar 50 µm. f ncontrol vehicle = 8, ncontrol montelukast = 9, nCIR vehicle = 6, nCIR montelukast = 5. CIR cranial irradiation, DCX doublecortin, GCL granule cell layer, SGZ subgranular zone. Error bars indicate ± SEM. Statistical results from two-way ANOVA are presented in the figures, ¤ = treatment (control/CIR), # = drug (vehicle/montelukast), * = interaction between treatment and drug. *P < 0.05, #P < 0.05, ¤¤¤¤P < 0.0001

Back to article page